Literature DB >> 4003284

Hemodynamic effects of nifedipine given alone and in combination with atenolol in patients with impaired left ventricular function.

M de Buitleir, E Rowland, D M Krikler.   

Abstract

The acute intravenous (IV) (0.1, 0.2 and 0.4 microgram/kg/min over 10 minutes each) and chronic oral (60 mg/day) administration of nifedipine was examined in 9 patients with significantly impaired left ventricular (LV) function (ejection fraction [EF] on radionuclide scanning was 0.20 to 0.40) who were already receiving beta-blocker therapy (greater than 25% reduction in peak exercise heart rate) with atenolol, 100 to 200 mg/day. The mean control LV end-diastolic pressure (EDP) at cardiac catheterization and EF for the group as a whole were 30 +/- 3 mm Hg (range 20 to 42) (mean +/- standard error of the mean) and 28.5 +/- 2.4%, respectively. Three of the 9 patients had hemodynamic deterioration and LV failure at some stage during the study, and their mean LVEDP and EF were 38 +/- 3 mm Hg (range 33 to 42) and 22.6 +/- 2.7%, respectively. In the 6 patients who tolerated the full treatment protocol, the mean LVEDP and EF were 26.5 +/- 2.0 mm Hg (range 20 to 35) and 31.5 +/- 2.8%, respectively. Seven patients received IV nifedipine, which had a negative inotropic action but did not precipitate cardiac decompensation. Chronic oral administration of nifedipine in combination with atenolol precipitated LV failure only in those with the lowest EF and highest LVEDP; usually LV failure was present with atenolol alone. Extensive infarction, frequently complicated by LV failure at the time, LVEDP greater than 32 mm Hg and control resting EF less than 30% were associated with LV failure.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4003284     DOI: 10.1016/0002-9149(85)91206-8

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  7 in total

1.  The cardiovascular effects of oral nifedipine and nicardipine: a double-blind comparison in healthy volunteers using transthoracic bioimpedance cardiography.

Authors:  S H Thomas; P Molyneux; J Kelly; S E Smith
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

2.  Evaluation of the rabbit Purkinje fibre assay as an in vitro tool for assessing the risk of drug-induced torsades de pointes in humans.

Authors:  Marion Aubert; Rolf Osterwalder; Björn Wagner; Isabelle Parrilla; Icilio Cavero; Lucette Doessegger; Eric A Ertel
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

Review 3.  Calcium channel antagonism and beta blockade in combination--a therapeutic alternative in cardiovascular disorders. A review.

Authors:  J N Lessem; B N Singh
Journal:  Cardiovasc Drugs Ther       Date:  1989-06       Impact factor: 3.727

4.  The total ischemic burden European trial (TIBET): design, methodology, and management. The TIBET Study Group.

Authors: 
Journal:  Cardiovasc Drugs Ther       Date:  1992-08       Impact factor: 3.727

5.  Atenolol-nifedipine combinations compared to atenolol alone in hypertension: efficacy and tolerability.

Authors:  D Maclean; E T Mitchell; R R Coulson; T J Fitzsimons; D G McDevitt
Journal:  Br J Clin Pharmacol       Date:  1988-04       Impact factor: 4.335

6.  Comparison of the cardiovascular effects of nifedipine and nicardipine in the presence of atenolol.

Authors:  S H Thomas
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

7.  Heart insufficiency after combination of verapamil and metoprolol: A fatal case report and literature review.

Authors:  Eva A Saedder; Asser Hedegård Thomsen; Jørgen Bo Hasselstrøm; Jakob Ross Jornil
Journal:  Clin Case Rep       Date:  2019-09-19
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.